MGMT and glioblastoma: In GBM patients who lack methylation at the MGMT promoter region, a GBM subpopulation presumably insensitive to TMZ treatment [30,31], we found that H2AFJ upregulation is able to further differentiate a poorer TMZ-responsive subgroup from those patients.